Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses
US8808693B2 · kind B2 · utility
1Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 1, 2010 |
| Grant date | Aug 19, 2014 |
| Priority date | — |
| Expiry date | May 18, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.